Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR mutation + MET mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

EGFR expression (46)

EGFR overexpression (34)

MET overexpression (32)

MET expression (12)

EGFR positive (8)

MET positive (8)

EGFR negative (6)

EGFR negative + ALK negative (4)

EGFR expression + ALK positive (3)

EGFRVIII expression + PTEN expression (3)

EGFRvIII expression (3)

EGFR expression + MET expression (2)

EGFR overexpression + HER-2 overexpression (2)

MMP17 expression + EGFR expression + RB1 expression (2)

MUC1 expression + EGFR expression (2)

TROP2 expression + EGFR expression (2)

MET overexpression + KDR overexpression (2)

MET overexpression + SYK overexpression (2)

TPBG expression + MET expression (2)

EGFR expression + HER-2 expression (1)

EGFR underexpression (1)

EGFRVIII overexpression (1)

EPHA2 overexpression + EGFR overexpression (1)

GPC3 positive + EGFR expression (1)

FGFR overexpression + MET overexpression (1)

MET expression + HER-2 expression (1)

MET overexpression + HER-2 overexpression (1)

MET overexpression + MUC5B overexpression (1)

MET underexpression (1)

DRD2 expression + EGFR overexpression (0)

YAP1 overexpression + EGFR overexpression (0)

PTGS2 positive + MET positive + TOPK positive + EGFR mutation (0)

EGFR expression (46)

EGFR overexpression (34)

MET overexpression (32)

MET expression (12)

EGFR positive (8)

MET positive (8)

EGFR negative (6)

EGFR negative + ALK negative (4)

EGFR expression + ALK positive (3)

EGFRVIII expression + PTEN expression (3)

EGFRvIII expression (3)

EGFR expression + MET expression (2)

EGFR overexpression + HER-2 overexpression (2)

MMP17 expression + EGFR expression + RB1 expression (2)

MUC1 expression + EGFR expression (2)

TROP2 expression + EGFR expression (2)

MET overexpression + KDR overexpression (2)

MET overexpression + SYK overexpression (2)

TPBG expression + MET expression (2)

EGFR expression + HER-2 expression (1)

EGFR underexpression (1)

EGFRVIII overexpression (1)

EPHA2 overexpression + EGFR overexpression (1)

GPC3 positive + EGFR expression (1)

FGFR overexpression + MET overexpression (1)

MET expression + HER-2 expression (1)

MET overexpression + HER-2 overexpression (1)

MET overexpression + MUC5B overexpression (1)

MET underexpression (1)

DRD2 expression + EGFR overexpression (0)

YAP1 overexpression + EGFR overexpression (0)

PTGS2 positive + MET positive + TOPK positive + EGFR mutation (0)

›

EGFR mutation + MET mutation	Non Small Cell Lung Cancer	EGFR mutation + MET mutation	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EGFR mutation + MET mutation	Non Small Cell Lung Cancer	EGFR mutation + MET mutation	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3